Subcutaneous Contraceptive and HIV Implant Engineered for Long-Acting Delivery (SCHIELD) device
Novel polymer reservoir MPT implant. Target 1 year duration. Active Ingredient: TBD antiretroviral + hormone.
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
Hormonal
Delivery Route & Method:
Systemic - Implant (Subcutaneous)
Mechanism of Action:
nucleoside reverse transcriptase inhibitor; ovulation suppression
Developer:
- Research Triangle International (RTI)
Funding:
- U.S. Agency for International Development (USAID)
Active Ingredient(s):
- Unspecified
Product Indication(s):
- HIV
- Pregnancy